rhinovirus infection; human metapneumovirus infection; Fetal exposure during pregnancy; The mother of the infant of unknown ethnic origin and unknown gender was participating in Moderna mRNA-1273 Observational Pregnancy Outcome Study and patient experienced RHINOVIRUS INFECTION (rhinovirus infection) and METAPNEUMOVIRUS INFECTION (human metapneumovirus infection). Additionally, the patient had FOETAL EXPOSURE DURING PREGNANCY (Fetal exposure during pregnancy).  Patient's mother did not have any of the tobacco or nicotine-containing products, cigarettes or marijuana or recreational drugs since last questionnaire.  Patient's mother  was consuming less than 3 drinks of caffeinated beverages and 1 to 9 alcoholic drinks per week. Patient's mother had history of Maternal exposure during pregnancy. Patient's mother not had COVID-19 infection which was confirmed by negative test. Patient's mother received following medications from the 28 days before or any time during/post this pregnancy- Cetirizine, Fluticasone propionate, Esomeprazole, Ibuprofen, Norethisterone, Acetaminophen.  Patient did not have a confirmed diagnosis of COVID-19.  The subject received the dose of mRNA-1273 for COVID-19 vaccination on an unknown date. On an unknown date, the subject experienced RHINOVIRUS INFECTION (rhinovirus infection) (seriousness criteria hospitalization) and METAPNEUMOVIRUS INFECTION (human metapneumovirus infection) (seriousness criteria hospitalization). Additionally, the subject had FOETAL EXPOSURE DURING PREGNANCY (Fetal exposure during pregnancy). The delivery occurred on 26-May-2022, birth type was reported as unknown, and the fetal outcome was Delivered NOS.  No treatment information was reported by the reporter.  The subjects last dose date prior to the event and the action taken with mRNA-1273 was unknown.  The outcome of the event RHINOVIRUS INFECTION (rhinovirus infection) and METAPNEUMOVIRUS INFECTION (human metapneumovirus infection) was reported as unknown, and for the event FOETAL EXPOSURE DURING PREGNANCY (Fetal exposure during pregnancy) it was reported as resolved.  The reporter did not provide the causality for event RHINOVIRUS INFECTION (rhinovirus infection), METAPNEUMOVIRUS INFECTION (human metapneumovirus infection) and FOETAL EXPOSURE DURING PREGNANCY (Fetal exposure during pregnancy).  It was reported that patient was delivered without any congenital anomalies and achieved all the developmental milestones.  Company comment:  This sponsored case concerns an infant patient of unknown age and gender with no reported medical history, who experienced the unexpected, serious (Hospitalization) events of Rhinovirus infection and Metapneumovirus infection. Foetal exposure during pregnancy was also reported. The exact date of administration of an unknown dose of mRNA-1273 vaccine and onset date of the events were not specified, hence latency could not be properly assessed. The report mentioned the patient was hospitalized for two days; however, no further clinical details were provided for medical reviewing. The outcome of the events was unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This sponsored case concerns an infant patient of unknown age and gender with no reported medical history, who experienced the unexpected, serious (Hospitalization) events of Rhinovirus infection and Metapneumovirus infection. Foetal exposure during pregnancy was also reported. The exact date of administration of an unknown dose of mRNA-1273 vaccine and onset date of the events were not specified, hence latency could not be properly assessed. The report mentioned the patient was hospitalized for two days; however, no further clinical details were provided for medical reviewing. The outcome of the events was unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.